IL140592A0 - Synthetic peptides and methods of use for autoimmune disease therapies - Google Patents

Synthetic peptides and methods of use for autoimmune disease therapies

Info

Publication number
IL140592A0
IL140592A0 IL14059299A IL14059299A IL140592A0 IL 140592 A0 IL140592 A0 IL 140592A0 IL 14059299 A IL14059299 A IL 14059299A IL 14059299 A IL14059299 A IL 14059299A IL 140592 A0 IL140592 A0 IL 140592A0
Authority
IL
Israel
Prior art keywords
methods
autoimmune disease
synthetic peptides
disease therapies
therapies
Prior art date
Application number
IL14059299A
Other languages
English (en)
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of IL140592A0 publication Critical patent/IL140592A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K4/00Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
IL14059299A 1998-07-23 1999-07-22 Synthetic peptides and methods of use for autoimmune disease therapies IL140592A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9385998P 1998-07-23 1998-07-23
US12367599P 1999-03-09 1999-03-09
PCT/US1999/016617 WO2000005249A2 (en) 1998-07-23 1999-07-22 Synthetic peptides and methods of use for autoimmune disease therapies

Publications (1)

Publication Number Publication Date
IL140592A0 true IL140592A0 (en) 2002-02-10

Family

ID=26787981

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14059299A IL140592A0 (en) 1998-07-23 1999-07-22 Synthetic peptides and methods of use for autoimmune disease therapies

Country Status (8)

Country Link
US (2) US7566767B2 (xx)
EP (3) EP1105414A2 (xx)
JP (1) JP2003521448A (xx)
AU (1) AU766498B2 (xx)
CA (1) CA2336238A1 (xx)
IL (1) IL140592A0 (xx)
WO (1) WO2000005249A2 (xx)
ZA (1) ZA200100366B (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
JP2003521448A (ja) * 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
IL161121A0 (en) * 2001-10-03 2004-08-31 Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
ES2349033T3 (es) 2001-12-04 2010-12-22 Teva Pharmaceutical Industries, Ltd. Procedimientos para la medida de la actividad del acetato de glatiramer.
DK1429800T3 (da) 2001-12-06 2009-04-27 Yeda Res & Dev Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose
EP1826217B1 (en) * 2002-10-02 2010-07-21 F.Hoffmann-La Roche Ag Method for identification of antigenic peptides
US8008258B2 (en) 2003-01-21 2011-08-30 Yeda Research And Development Co. Ltd. Cop 1 for treatment of inflammatory bowel diseases
JP5456235B2 (ja) 2003-11-12 2014-03-26 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経変性疾患を治療するためのワクチン及び方法
PL1701730T3 (pl) 2003-12-09 2014-04-30 Yeda Res & Dev Sposób i szczepionka zawierająca kopolimer 1 do leczenia zaburzeń psychicznych
WO2005120542A2 (en) 2004-05-07 2005-12-22 Peptimmune, Inc. Methods of treating disease with random copolymers
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
SI1797109T1 (sl) * 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
US20070264229A1 (en) * 2004-09-13 2007-11-15 Strominger Jack L Peptides for Treatment of Autoimmune Disease
US20090130121A1 (en) * 2005-02-02 2009-05-21 Yeda Research And Development Co., Ltd. Synthetic Peptide Copolymers for Treatment and Prevention of Cardiovascular Disorders
CA2649296A1 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
US9089509B2 (en) 2006-06-28 2015-07-28 Yeda Research And Development Co., Ltd. Method of treatment of age-related macular degeneration
WO2009018477A2 (en) * 2007-07-31 2009-02-05 Cognosci, Inc. Methods of inhibiting calcineurin with apoe analogs
BRPI0817682A2 (pt) 2007-10-16 2015-04-07 Peptimmune Inc Métodos para projetar e preparar vacinas compreendendo composições de polímero de sequência direcionada via a expansão direta de epítopos
ES2612001T4 (es) 2009-08-20 2018-02-07 Yeda Research & Development Company, Ltd. Terapia de baja frecuencia con acetato de glatirámero
EA022399B1 (ru) * 2009-11-17 2015-12-30 Арес Трейдинг С.А. Способы улучшения дизайна, биодоступности и эффективности композиций полимеров со случайной последовательностью путем основанной на сыворотке детекции композиций полимеров со случайной последовательностью
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
NZ609938A (en) 2010-10-11 2015-11-27 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
EP2667888A4 (en) * 2011-01-28 2015-11-11 Univ Oregon Health & Science LIGMPHES OF RECOMBINANT T LYMPHOCYTES AND ANTIBODIES BINDING TO LYMPHOCYTES B FOR THE TREATMENT OF AUTOIMMUNE DISEASES
JP2014530819A (ja) 2011-10-10 2014-11-20 テバ ファーマシューティカル インダストリーズ リミティド 酢酸グラチラマーに対する臨床的応答性を予測するために有用な一塩基多形
EP2906719A4 (en) 2012-10-10 2016-11-09 Teva Pharma PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
NZ747418A (en) 2014-03-12 2023-05-26 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
WO2019175869A1 (en) 2018-03-12 2019-09-19 Yeda Research And Development Co. Ltd Treatment of a heart disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US6066621A (en) 1989-12-10 2000-05-23 Yeda Research And Development Co. Ltd. Synthetic peptides for the treatment of myasthenia gravis
WO1992002543A1 (en) * 1990-08-01 1992-02-20 Cytel Corporation Novel immunosuppressant peptides
US5679640A (en) * 1991-02-12 1997-10-21 Cytel Corporation Immunosuppressant peptides
US5583031A (en) 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
IL106065A (en) 1992-06-18 1999-10-28 Yeda Res & Dev Synthetic peptides for the treatment of myasthenia gravis and preparations containing them
US6696061B1 (en) 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
WO1994026774A1 (en) * 1993-05-19 1994-11-24 Cytel Corporation Novel treatments for allergic diseases
US5576419A (en) * 1993-06-30 1996-11-19 Regents Of The University Of Minnesota Mild solid-phase synthesis of aligned branched triple-helical peptides
ES2318848T3 (es) 1993-09-14 2009-05-01 Pharmexa Inc. Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria.
CA2186873A1 (en) * 1994-04-01 1995-10-12 Charles J. Hackett Haptenated peptides and uses thereof
WO1995031997A1 (en) * 1994-05-20 1995-11-30 UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE ARMY Model for testing immunogenicity of peptides
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
WO1997049430A1 (en) 1996-06-26 1997-12-31 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
AU730477B2 (en) 1996-08-05 2001-03-08 President And Fellows Of Harvard College MHC binding peptide oligomers and methods of use
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
JP2003521448A (ja) * 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
US6514938B1 (en) * 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
DE60112718T2 (de) * 2000-01-20 2006-06-29 Yeda Research And Development Co., Ltd. Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
IL161121A0 (en) * 2001-10-03 2004-08-31 Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
JP2007500693A (ja) * 2003-07-31 2007-01-18 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 移植片拒絶反応を予防するための合成ペプチドコポリマーを含む併用療法

Also Published As

Publication number Publication date
AU766498B2 (en) 2003-10-16
EP2327712A3 (en) 2011-09-14
EP1105414A2 (en) 2001-06-13
WO2000005249A2 (en) 2000-02-03
ZA200100366B (en) 2002-01-14
JP2003521448A (ja) 2003-07-15
CA2336238A1 (en) 2000-02-03
EP2848627A3 (en) 2015-04-01
AU5223499A (en) 2000-02-14
US20040006022A1 (en) 2004-01-08
US7566767B2 (en) 2009-07-28
EP2848627A2 (en) 2015-03-18
EP2327712B1 (en) 2014-10-15
WO2000005249A3 (en) 2000-10-05
US9066905B2 (en) 2015-06-30
EP2327712A2 (en) 2011-06-01
US20080207526A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
IL140592A0 (en) Synthetic peptides and methods of use for autoimmune disease therapies
HUP0103321A3 (en) Peptide antagonists of zonulin and methods for use of the same
EP0880356A4 (en) ANTIMICROBIAL PEPTIDES AND METHODS OF USE THEREOF
EP0785276A4 (en) MODIFICATION OF A PEPTIDE AND A PROTEIN
HK1096974A1 (en) Antibody against human parathormone related peptides
ZA969443B (en) Peptides which enhance transport across tissues and methods of identifying and using the same
EP1037911A4 (en) ANTI-PATHOGEN SYSTEM AND METHOD FOR USE THEREOF
EP1071706A4 (en) FAST DEGRADABLE GFP FUSION PROTEINS AND METHOD OF USE THEREOF
HUP9903378A3 (en) Autoantigen and proteins structurally related thereto for use in immunotherapy of autoimmune diseases
EP0831793A4 (en) PROTEIN PARTICLES FOR THERAPEUTIC AND DIAGNOSTIC USE
HUP9900147A3 (en) Therapeutic agents and autoimmune diseases
IL129024A0 (en) Use of proteins as agent against autoimmune diseases
IL131929A0 (en) Rap protein its preparation and use
HUP9801680A3 (en) Peptides and remedy for autoimmune diseases comprising the same
AU1087797A (en) Clip analogues and autoimmune disease
GB9918155D0 (en) Proteins and peptides
EP1046036A4 (en) METHODS OF OBTAINING PEPTIDE FUNCTION PROBES
IL120759A0 (en) Modulators of the function of fas receptors and other proteins
AU3964499A (en) Agouti-related protein analogs and methods of use
EP1119251A4 (en) METHOD FOR SCREENING ON ANALOG BONE THERAPY ACTIVE SUBSTANCES THAT CONTROL APOPTOSIS AND THEIR USE
GB9714276D0 (en) Peptides and related compounds
IL147345A0 (en) Drosphila recombination- associated protein and methods for use
EP0797582A4 (en) PHOSPHOTYROSIN EXAMINATION AND PEPTIDES FOR THIS
IL140825A0 (en) Peptides for use in immunotherapy of autoimmune diseases
HK1024006A1 (en) Peptide as diagnostic and therapeutic agent for autoimmune diseases